期刊文献+

基于点击化学反应的半乳糖糖基化马蹄金素衍生物的合成及抗HBV活性

Synthesis and Anti-HBV Activity Evaluation of the Galactopyranosyl Derivatives of MTS Based on Click Reaction
下载PDF
导出
摘要 以D-半乳糖和二缩三乙二醇为原料,经乙酰化、糖基化和叠氮化钠取代等反应合成了带叠氮连接臂的半乳糖配基,通过点击化学反应将其与炔丙基修饰的马蹄金素(MTS)衍生物进行连接,设计合成了6个具有潜在肝靶向性的半乳糖糖基化MTS衍生物.通过1H NMR,13C NMR,1H-1H COSY,HMQC,DEPT和ESI-MS对其结构进行了表征;采用Hep G2 2.2.15细胞模型初步评价了目标化合物的抗乙型肝炎病毒(HBV)活性.结果表明,所有目标化合物对HBV DNA的复制均有抑制作用,且具有一定的量效关系;化合物15f在50μg/m L浓度下对Hep G2 2.2.15细胞株的抑制率为83%,具有进一步研究的价值. Matijin-Su [N-( N-benzoyl-L-phenylalanyl)-O-acetyl-L-phenylalanol,MTS],a dipeptide derivative,was isolated from a Chinese ethnic drug Matijin( Dichondra repens Forst.) which has been widely used in the treatment of chronic liver disease as folk medicine in China. A series of MTS derivatives with anti-hepatitis B virus( HBV) activitiy was synthesized by structural modification of MTS. One of MTS derivatives named"Tyrophentide"had been finished pre-clinical research and has been approved to do clinical study of phase Ⅰby China Food and Drug Administration( CFDA). The preliminary pharmacokinetic experiments showed that it was widely distributed in many organs,and the concentration in liver was low. To improve the concentration in liver lesion tissue and increase the anti-HBV activity of MTS derivatives,a series of hepatic targeting galactopyranosyl derivatives of MTS 15a—15f was designed according to asialoglycoprotein receptor( ASGP-R)mediation and synthesized. Starting from unexpensive and commercially available galactose and triethylene glycol,the glycosyl donor with azide linker was achieved via acetylation,glycosylation and azidation reaction. At the same time,propargylated MTS derivatives using L-phenylalaninol,L-tyrosine methyl ester hydrochloride,benzoic acid and its derivatives as the starting materials were prepared by acylation,hydrolysis,alkylation,condensation reactions and so on. Then compounds 15a—15f with a 1,2,3-triazole unit were obtained from"click"chemistry reaction using copper( Ⅰ) catalyst in high yield( over 85%),which were deacetylated in the 0. 41 mol / L solution of sodium methoxide to give target compounds. The structures of target compounds were confirmed by1 H NMR,13 C NMR,1H-1H COSY,HMQC,DEPT and ESI-MS. The anti-HBV activities of target compounds were evaluated in Hep G2 2. 2. 15 cells. The screening results showed that all target compounds had inhibitory effect on HBV DNA replication in Hep G2 2. 2. 15 cells. Compound 15 f showed inhibition rate anti-HBV activity of 83% at 50 μg / m L and could be worthy of further research.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2016年第7期1307-1319,共13页 Chemical Journal of Chinese Universities
基金 国家自然科学基金(批准号:81360472) “西部之光”人才项目(2014年)资助
关键词 肝靶向 半乳糖 马蹄金素衍生物 点击化学 抗HBV活性 Hepatic targeting Galactose Derivatives of Matijin-Su "Click "chemistry Anti-hepatitis B virus activity
  • 相关文献

参考文献24

  • 1Lozano R. , Naghavi M. , Foreman K. , Lim S. , Shibuya K. J. , Aboyans V. , Lancet, 2012, 380(9859), 2095-2128.
  • 2Goulis I. , Karatapanis S. , Akriviadis E. , Deutsch M. , Dalekos G. N. , Raptopoulou-Gigi M. , Mimidis K. , Germanidis G. , Drakoulis C. , Triantos C. , Zintzaras E. , Bakalos G. , Papatheodoridis G. , Liver Int. , 2015, 35(5) , 1540-1548.
  • 3梁光平,胡占兴,刘青川,黄正明,张建新,梁光义,徐必学.马蹄金素杂环衍生物的合成及抗乙肝病毒活性[J].高等学校化学学报,2014,35(11):2353-2359. 被引量:10
  • 4QiuJ. Y., XuB. X., HuangZ. M., PanW. D., CaoP. X., LiuC. X., HaoX. J., SongB. A., LiangG. Y., Bioorg. Med. Chem. , 2011, 19(18), 5352-5360.
  • 5邱净英,黄正明,潘卫东,曹佩雪,梁光义.马蹄金素衍生物的合成及抗乙肝病毒活性[J].中国药科大学学报,2012,43(5):390-394. 被引量:16
  • 6梁光平,曹佩雪,杨秀虾,黄正明,刘青川,梁光义,徐必学.NO供体型马蹄金素衍生物的合成及其初步的抗乙肝病毒活性[J].有机化学,2014,34(5):973-979. 被引量:9
  • 7Spiess M., Biochem. , 1990, 29(43) , 10009-10018.
  • 8DingJ. X., Xiao C. S., Li Y., ChengY. L., Wang N. N., He C. L., ZhuangX. L., Zhu X. J. , Chen X. S., J. Control. Release, 2013, 169(3), 193-203.
  • 9WangY. Q., SuJ.,CaiW. W., LuP., YuanL. F., JinT., ChenS. Y., ShengJ.,Drug. Des. Devel. Ther. ,2013, 7(3),211- 221.
  • 10Naicker K. , Ariatti M. , Singh M. , Colloids Surfaces B: Biointerfaces, 2014, 122, 482-490.

二级参考文献38

  • 1邓艳君,石静波,姜力勋,高静,姚其正.嘧啶并呋咱核苷衍生物的制备及其活性初探[J].化学学报,2006,64(18):1911-1915. 被引量:10
  • 2Pang R,Tao JY,Zhang SL,ef al. In vitro antiviral activity of lute-in against hepatitis B virus [ J]. Phyiother Res,2010,24 (11):1627-1 630.
  • 3Lin KW,Kirchner JT. Information from your family doctor:hepati-tis B infection [ J ]. Am Farn Physician ,2004,69 (1) :86.
  • 4Park N,Song I,Chung Y. Chronic hepatitis B in hepatocarcino-genesis[ J] ? Postgrad Med 7,2006,82(970) :507 -515.
  • 5Karayiannis P. Current therapies for chronic hepatitis B virus in-fection[ J]. Expert Rev Anti Infect 77ier,2004,2(5) :745 -760.
  • 6Fattovich G,Brollo L,Giustina G,et al. Natural-history and prog-nostic factors for chronic hepatitis type B[ J]. Gul,1991,32(3);294 -298.
  • 7Lavanchy D. Hepatitis B virus epidemiology, disease burden,treatment,and current and emerging prevention and control meas-ures[ J]. J Viral Hepat,2Q04,11(2) :97 - 107.
  • 8Mast EE,Alter MJ,Margolis HS. Strategies to prevent and controlhepatitis B and C virus infections : a global perspective [ J ].Vaccirie,1999,17(13/14) :1 730 -1 733.
  • 9Shaw T, Bartholomeusz A, Locamini S. HBV drug resistance:mechanisms,detection and interpretation[ J]. J Hepatol,2006,44(3):593 -606.
  • 10Yang WJ,Sun KG,Liu CR,ef al. Analysis report of anti-hepatitisB virus drug[ J]. 中国现代药物应用[J]. 2009,3( 19):87 -88.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部